Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGB6 | P18564 | 14/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245661 | 0.86 | ITGAV (0.49) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4200668 | 0.84 | ITGB3 (0.65) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4193839 | 0.83 | ITGB3 (0.56) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4749452 | 0.81 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL4245742 | 0.79 | ITGB1 (0.58) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4197149 | 0.78 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4191727 | 0.77 | ITGB1 (0.50) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL24683292 | 0.77 | ITGAV (0.61) | ITGAVITGB3ITGB6 | |
| SCHEMBL29813809 | 0.77 | ITGAV (0.61) | ITGAVITGB3ITGB6 | |
| SCHEMBL21852991 | 0.77 | ITGAV (0.61) | ITGAVITGB3ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008125811-A1 | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGB5 | ITGAV 9/4885ITGB3 5/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.